Bicycle Therapeutics Announces Four Abstracts Accepted for Presentation at the ESMO Congress 2024
Bicycle Therapeutics (NASDAQ: BCYC) announced the acceptance of four abstracts for poster presentation at the ESMO Congress 2024 in Barcelona. The presentations will cover:
1. Updated results of BT8009 monotherapy in metastatic urothelial carcinoma patients
2. Peripheral neuropathy following treatment with BT8009 or BT5528 in advanced solid tumors
3. Phase 1/2 study of BT5528 in patients with advanced solid tumors
4. Initial results from a phase 1/2 study of BT7480 in patients with advanced solid tumors
These presentations highlight Bicycle's progress in developing its proprietary bicyclic peptide (Bicycle®) technology for various cancer treatments. The posters will be available on the company's website after the presentations.
Bicycle Therapeutics (NASDAQ: BCYC) ha annunciato l'accettazione di quattro abstract per presentazioni poster al Congresso ESMO 2024 a Barcellona. Le presentazioni copriranno:
1. Risultati aggiornati della monoterapia con BT8009 in pazienti con carcinoma uroteliale metastatico
2. Neuropatia periferica dopo il trattamento con BT8009 o BT5528 in tumori solidi avanzati
3. Studio di fase 1/2 di BT5528 in pazienti con tumori solidi avanzati
4. Risultati iniziali da uno studio di fase 1/2 di BT7480 in pazienti con tumori solidi avanzati
Queste presentazioni evidenziano i progressi di Bicycle nello sviluppo della sua tecnologia proprietaria di peptide biciclico (Bicycle®) per vari trattamenti oncologici. I poster saranno disponibili sul sito web dell'azienda dopo le presentazioni.
Bicycle Therapeutics (NASDAQ: BCYC) anunció la aceptación de cuatro resúmenes para presentación en cartel en el Congreso ESMO 2024 en Barcelona. Las presentaciones cubrirán:
1. Resultados actualizados de la monoterapia con BT8009 en pacientes con carcinoma urotelial metastásico
2. Neuropatía periférica tras el tratamiento con BT8009 o BT5528 en tumores sólidos avanzados
3. Estudio de fase 1/2 de BT5528 en pacientes con tumores sólidos avanzados
4. Resultados iniciales de un estudio de fase 1/2 de BT7480 en pacientes con tumores sólidos avanzados
Estas presentaciones destacan los avances de Bicycle en el desarrollo de su tecnología de péptido bicíclico (Bicycle®) para diversos tratamientos oncológicos. Los carteles estarán disponibles en el sitio web de la empresa después de las presentaciones.
바이시클 테라퓨틱스 (NASDAQ: BCYC)는 바르셀로나에서 열리는 ESMO 총회 2024 포스터 발표를 위해 네 개의 초록이 수락되었음을 발표했습니다. 발표 내용은 다음과 같습니다:
1. 전이성 요로상피암 환자를 위한 BT8009 단독요법의 업데이트된 결과
2. 진행성 고형종양에서 BT8009 또는 BT5528 치료 후의 말초신경병증
3. 진행성 고형종양 환자를 대상으로 한 BT5528의 1/2상 연구
4. 진행성 고형종양 환자를 대상으로 한 BT7480의 1/2상 연구 초기 결과
이 발표들은 다양한 암 치료를 위해 자사의 이차적 peptide (Bicycle®) 기술을 개발하는 바이시클의 진행 상황을 강조합니다. 발표 후 포스터는 회사 웹사이트에서 확인할 수 있습니다.
Bicycle Therapeutics (NASDAQ: BCYC) a annoncé l'acceptation de quatre résumés pour présentation en affichage lors du Congrès ESMO 2024 à Barcelone. Les présentations couvriront :
1. Résultats mis à jour de la monothérapie avec BT8009 chez des patients atteints de carcinome urothélial métastatique
2. Neuropathie périphérique suite au traitement par BT8009 ou BT5528 dans des tumeurs solides avancées
3. Étude de phase 1/2 de BT5528 chez des patients atteints de tumeurs solides avancées
4. Résultats initiaux d'une étude de phase 1/2 de BT7480 chez des patients atteints de tumeurs solides avancées
Ces présentations mettent en lumière les progrès de Bicycle dans le développement de sa technologie de peptide bicyclique (Bicycle®) pour divers traitements du cancer. Les affiches seront disponibles sur le site de l'entreprise après les présentations.
Bicycle Therapeutics (NASDAQ: BCYC) gab die Annahme von vier Abstracts für eine Posterpräsentation beim ESMO-Kongress 2024 in Barcelona bekannt. Die Präsentationen werden folgende Themen abdecken:
1. Aktualisierte Ergebnisse der Monotherapie mit BT8009 bei Patienten mit metastasiertem Urothelkarzinom
2. Periphere Neuropathie nach Behandlung mit BT8009 oder BT5528 bei fortgeschrittenen soliden Tumoren
3. Phase 1/2 Studie von BT5528 bei Patienten mit fortgeschrittenen soliden Tumoren
4. Erste Ergebnisse einer Phase 1/2 Studie zu BT7480 bei Patienten mit fortgeschrittenen soliden Tumoren
Diese Präsentationen heben die Fortschritte von Bicycle bei der Entwicklung seiner proprietären bikontaktpeptide (Bicycle®) Technologie zur Behandlung verschiedener Krebserkrankungen hervor. Die Poster sind nach den Präsentationen auf der Unternehmenswebsite verfügbar.
- Four abstracts accepted for presentation at ESMO Congress 2024, showcasing progress in multiple clinical trials
- Presentations cover various cancer treatments using Bicycle's proprietary technology, demonstrating pipeline diversity
- None.
Poster Presentation Details:
Title: BT8009 monotherapy in enfortumab vedotin-naïve patients with metastatic urothelial carcinoma (mUC): Updated results of Duravelo-1
Poster Session Title: Poster session 01
Date and Time: Saturday, Sept. 14, at 9-10 a.m. CEST
Presentation Number: 652P
Speaker: Oscar Reig Torras, M.D., Hospital Clinic de
Title: Peripheral neuropathy following treatment with Bicycle Toxin Conjugates® BT8009 or BT5528 monotherapy in patients with advanced solid tumors
Poster Session Title: Poster session 01
Date and Time: Saturday, Sept. 14, at 9-10 a.m. CEST
Presentation Number: 654P
Speaker: Bernard Doger de Spéville, M.D., Ph.D., START Madrid-FJD and Hospital Universitario Fundacion Jimenez Diaz
Title: EphA2-targeting Bicycle® Toxin Conjugate BT5528 in patients with advanced solid tumors: A phase 1/2 study
Poster Session Title: Poster session 01
Date and Time: Saturday, Sept.14, at 9-10 a.m. CEST
Presentation Number: 647P
Speaker: Elisa Fontana, M.D., Ph.D., Sarah Cannon Research Institute
Title: Initial results from a phase 1/2 study of BT7480, a novel Nectin-4/CD137 Bicycle Tumor-Targeted Immune Cell Agonist®, in patients with advanced solid tumors
Poster Session Title: Poster session 01
Date and Time: Saturday, Sept.14, at 9-10 a.m. CEST
Presentation Number: 650P
Speaker: Kyriakos P. Papadopoulos, M.D., START
The posters will be made available in the Publications section of bicycletherapeutics.com following the presentations.
About Bicycle Therapeutics
Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin (formerly BT8009), a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radio Conjugates (BRC™) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology.
Bicycle Therapeutics is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240722899403/en/
Investors:
Stephanie Yao
SVP, Investor Relations and Corporate Communications
ir@bicycletx.com
857-523-8544
Media:
Argot Partners
Deborah Elson
media@bicycletx.com
212-600-1902
Source: Bicycle Therapeutics plc
FAQ
What is the stock symbol for Bicycle Therapeutics?
How many abstracts from Bicycle Therapeutics were accepted for ESMO Congress 2024?
What is BT8009 being studied for in Bicycle Therapeutics' clinical trials?
What is the focus of the BT7480 study presented by Bicycle Therapeutics at ESMO 2024?
